[The use of sodium nitroprusside (Nipruton) in ischemia-related acute heart insufficiency].
By controlled vasodilation with nitroprusside sodium we succeed in improving the negative haemodynamic effects of the pumping insufficiency in myocardial ischamia. Increased filling pressures decrease, volumes of output increase in clearly decreased oxygen consumption of the myocardium. The influence on the time volume of the heart depends on the height and reaction of the filling pressure on nitroprusside sodium. In normal LVEDP the time volume of the heart decreases by nitroprusside sodium. The local function of the heart may clearly be improved under nitroprusside sodium in ischaemia. Altogether the hitherto got results in man are not homogeneously interpreted. Problems result from in form of therapy necessary frequent controls of the filling pressures and volumes of output as well as from the possible decrease of the time volume of the heart and the critical reduction of the perfusion pressure. According to own results of experiments on animals the sequelae of ischaemia may be reduced under the infusion of nitroprusside sodium. The restricted regional function of the heart is particularly improved. An obligatory judgment concerning the temporarily restricted use of nitroprusside sodium in the pumping insufficiency conditioned by ischaemia is not yet possible. A complicating effect have the individually different dose-effect-relations as well as not foreseeable haemodynamic results as a sequel of the basic disease in the complicated myocardiac infarction which is to be regarded as indication.
D000818:Animals; D002118:Calcium / Q000378:metabolism; D003327:Coronary Disease / Q000188:drug therapy*; D005292:Ferricyanides / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects; D006334:Heart Function Tests; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy; D009206:Myocardium / Q000378:metabolism; D009599:Nitroprusside / Q000008:administration & dosage / Q000494:pharmacology*; D010101:Oxygen Consumption; D013552:Swine; D014665:Vasodilator Agents / Q000494:pharmacology
D005292:Ferricyanides; D014665:Vasodilator Agents; D009599:Nitroprusside; D002118:Calcium
Zur Anwendung von Nitroprussid-Natrium (Nipruton) bei der ischämiebedingten akuten Herzinsuffizienz.